Galmed Pharmaceuticals Ltd (GLMD)

May 03, 2025

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Short Interest Up 41.3% in April - Defense World

May 03, 2025

May 01, 2025

Biotech Alert: Searches spiking for these stocks today - Yahoo Finance

May 01, 2025

Apr 30, 2025

Galmed Pharmaceuticals Ltd (GLMD) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - Sete News

Apr 30, 2025

Apr 29, 2025

Understanding the Risks of Investing in Galmed Pharmaceuticals Ltd (GLMD) - knoxdaily.com

Apr 29, 2025

Apr 29, 2025

Galmed Pharmaceuticals (NASDAQ:GLMD) Shares Cross Below 200 Day Moving Average – What’s Next? - Defense World

Apr 29, 2025

Apr 29, 2025

StockNews.com Begins Coverage on Galmed Pharmaceuticals (NASDAQ:GLMD) - Defense World

Apr 29, 2025

Apr 28, 2025

Galmed Pharmaceuticals (GLMD) Collaborates with VCU to Tackle GI Cancer Drug Resistance - GuruFocus

Apr 28, 2025

Apr 28, 2025

GLMD’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com

Apr 28, 2025

Apr 28, 2025

Understanding GLMD stock ratios for better investment decisions - uspostnews.com

Apr 28, 2025

Apr 28, 2025

Crude Oil Down 2%; Roper Technologies Increases 2025 Outlook - Benzinga

Apr 28, 2025

Apr 28, 2025

Is Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) Stock Worth Investing In for High Returns? - Marketing Sentinel

Apr 28, 2025

Apr 28, 2025

Galmed Signs Term Sheet to Develop New Semaglutide Formulation; Shares Up - marketscreener.com

Apr 28, 2025

Apr 28, 2025

Galmed (GLMD) Shares Climb Amid Strategic Drug Delivery Development - Stocks Telegraph

Apr 28, 2025

Apr 28, 2025

Galmed Pharmaceuticals Signs Agreement for Novel Semaglutide Formulation - TipRanks

Apr 28, 2025

Apr 28, 2025

Galmed (GLMD) Pharmaceuticals Signs Licensing Agreement for Drug - GuruFocus

Apr 28, 2025

Apr 28, 2025

Galmed Signed Term Sheet For The Development Of Novel Semaglutide Sublingual Formulation - marketscreener.com

Apr 28, 2025

Apr 28, 2025

Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation - PR Newswire

Apr 28, 2025

Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025

Apr 21, 2025

Galmed Pharmaceuticals (NASDAQ:GLMD) Coverage Initiated at StockNews.com - Defense World

Apr 21, 2025

Apr 17, 2025

Galmed partners with VCU to target drug resistance - The Pharma Letter

Apr 17, 2025

Apr 17, 2025

Galmed Pharmaceuticals Partners with VCU to Combat Drug Resistance in GI Cancers - TipRanks

Apr 17, 2025

Apr 17, 2025

Galmed Pharmaceuticals Launches VCU Collaboration To Tackle Drug Resistance In Gi Cancers - marketscreener.com

Apr 17, 2025

Apr 17, 2025

Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers - PR Newswire

Apr 17, 2025

Apr 15, 2025

Galmed reports key biomarkers for heart and liver health By Investing.com - Investing.com South Africa

Apr 15, 2025

Apr 15, 2025

Galmed Pharmaceuticals Unveils New Blood Markers for Aramchol - TipRanks

Apr 15, 2025

Apr 15, 2025

Galmed reports key biomarkers for heart and liver health - Investing.com

Apr 15, 2025

Apr 15, 2025

Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor - Kilgore News Herald

Apr 15, 2025

Apr 13, 2025

Galmed Pharmaceuticals (NASDAQ:GLMD) Now Covered by Analysts at StockNews.com - Defense World

Apr 13, 2025

Apr 10, 2025

Galmed Pharmaceuticals Reports Positive Results from AM-001 Study of Aramchol Meglumine - TipRanks

Apr 10, 2025

Apr 10, 2025

Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor - PR Newswire

Apr 10, 2025

Apr 06, 2025

Maxim Group Reiterates “Hold” Rating for Galmed Pharmaceuticals (NASDAQ:GLMD) - Defense World

Apr 06, 2025

Apr 05, 2025

Galmed Pharmaceuticals (NASDAQ:GLMD) Earns Sell Rating from Analysts at StockNews.com - Defense World

Apr 05, 2025

Apr 04, 2025

Galmed Phar stock hits 52-week low at $1.32 amid challenges - Investing.com Australia

Apr 04, 2025

Apr 04, 2025

Galmed Phar stock hits 52-week low at $1.32 amid challenges By Investing.com - Investing.com South Africa

Apr 04, 2025

Apr 02, 2025

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024 - Yahoo Finance

Apr 02, 2025

Mar 28, 2025

Galmed Pharmaceuticals (NASDAQ:GLMD) Now Covered by StockNews.com - Defense World

Mar 28, 2025

Mar 27, 2025

Galmed Phar stock hits 52-week low at $1.66 amid challenges - Investing.com India

Mar 27, 2025

Mar 27, 2025

Galmed Phar stock hits 52-week low at $1.66 amid challenges By Investing.com - Investing.com South Africa

Mar 27, 2025

Mar 20, 2025

Galmed Pharmaceuticals Secures New Patent for NASH Therapy - TipRanks

Mar 20, 2025

Mar 20, 2025

Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination Therapy - PR Newswire

Mar 20, 2025

Mar 20, 2025

Galmed Pharmaceuticals (NASDAQ:GLMD) Coverage Initiated by Analysts at StockNews.com - Defense World

Mar 20, 2025

Mar 17, 2025

Can Galmed Pharmaceuticals Ltd (GLMD) meet market expectations this quarter? - uspostnews.com

Mar 17, 2025

Mar 13, 2025

Galmed Phar stock hits 52-week low at $1.75 amid challenges - Investing.com Australia

Mar 13, 2025

Mar 13, 2025

Galmed Phar stock hits 52-week low at $1.75 amid challenges By Investing.com - Investing.com South Africa

Mar 13, 2025

Mar 12, 2025

Galmed Pharmaceuticals (NASDAQ:GLMD) Share Price Passes Below Two Hundred Day Moving Average – Here’s What Happened - Defense World

Mar 12, 2025

Feb 28, 2025

Galmed Pharmaceuticals Ltd. to Host Earnings Call - ACCESS Newswire

Feb 28, 2025

Feb 27, 2025

Galmed Phar stock hits 52-week low at $2.21 amid challenges - Investing.com Australia

Feb 27, 2025

Feb 26, 2025

Galmed Phar stock hits 52-week low at $2.21 amid challenges By Investing.com - Investing.com South Africa

Feb 26, 2025